MISSISSAUGA, ONTARIO--(Marketwire - May 30, 2008) - BioSyent Inc. ("BioSyent")(TSX VENTURE: RX) today released a summary of its financial results for the first quarter 2008. For the three months ending March 31, 2008, sales decreased by 4.9% from $302,840 in quarter one 2007 to $287,997 in quarter one 2008. The company incurred a loss of ($74,067) in quarter one 2008 compared to a loss of ($29,416) in quarter one 2007. This loss is predominantly due to higher operating expenses leading up to the launch of Ciprofloxacin Injection which was first shipped in May 2008 and lower sales of Protect-It® in quarter one 2008 as compared to quarter one 2007.